Compare Dyne Therapeutics Inc. Common Stock (DYN) vs Qnity Electronics Inc. Common Stock (Q) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dyne Therapeutics Inc. Common Stock vs Qnity Electronics Inc. Common Stock — how do they compare? Dyne Therapeutics Inc. Common Stock trades at $15.04 (market cap $2.81B), while Qnity Electronics Inc. Common Stock trades at $117.55 (market cap $25.44B). The key difference: Qnity Electronics Inc. Common Stock is far larger — about 9.1× Dyne Therapeutics Inc. Common Stock's market cap, and Qnity Electronics Inc. Common Stock pays a 0.26% dividend while Dyne Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Dyne Therapeutics Inc. Common Stock for 0 Days and Qnity Electronics Inc. Common Stock for 6 Days on average.
| DYN | Q | |
|---|---|---|
Market Cap | $2.81B | $25.44B |
Volume | 2,195,902 | 1,971,734 |
Sector | Health | Technology |
52-Week High | $26.78 | $175.64 |
52-Week Low | $14.60 | $73.54 |
Typical Hold Time | 0 Days | 6 Days |
Enterprise Value | $2.13B | $28.50B |
Dividend Yield | — | 0.26% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dyne Therapeutics (DYN) trades at $15.30, down 4.14% on the day, reflecting recent volatility amid mixed clinical trial news. The stock is in a neutral technical position with immediate support at $15 and resistance at $16. Fundamentally, the company is a clinical-stage biotech with no revenue, reporting a net loss of $446.21M in 2025, but maintains strong analyst support with an 85.7% buy rating and a $35.20 consensus price target. Recent news highlights progress in Phase 1/2 trials for neuromuscular diseases and a $375M public offering in July 2026 to fund development.
The investment case hinges on clinical success, offering significant upside to the price target, but carries high risk due to pre-revenue status, dependence on trial outcomes, and negative cash flow from operations. Investor sentiment is cautiously optimistic, buoyed by analyst confidence, though volatility from sector-specific news remains a near-term challenge.
Qnity Electronics (Q) trades at $122.95, down 0.21% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. Revenue grew to $4.75B in 2025, though net income margin is expected to dip in 2026. Recent news highlights product launches in AI data center cooling and advanced packaging, alongside inclusion in the PHLX Semiconductor Index.
The stock presents a mixed outlook: strong analyst consensus (100% buy ratings) and a $180 price target suggest significant upside, but technical weakness and a high P/E ratio of 43.9 pose risks. Key opportunities include AI-driven demand and advanced packaging growth, while risks involve execution in a competitive semiconductor market and potential margin pressure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Dyne Therapeutics Inc. Common Stock
Dyne Therapeutics, Inc. is a clinical-stage biotechnology company developing therapeutics for genetically driven neuromuscular diseases, including Duchenne muscular dystrophy and myotonic dystrophy type 1, with additional preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease.
Read more on DYN →About Qnity Electronics Inc. Common Stock
Qnity Electronics provides materials and solutions for semiconductor manufacturing and electronic systems. Its portfolio supports chip fabrication, advanced packaging, interconnects, and thermal management.
Read more on Q →
